Genotyping

Genotype testing will provide a genetic basis for target identification, toxicity prediction, dosing determination and for making treatment decisions.Using the focused combination of genetic and protein biomarkers to screen for biological activity increases the likelihood of useful clinical activity. Examples include UGT1A1 genotyping for Irinotecan toxicity prediction, CYP2C9 genotyping for warfarin dosing optimization and CYP2D6 genotyping to help in tamoxifen therapy management for breast cancer patients.

Genetic biomarkers are important in the drug development process because they can provide information about the potential risk associated with specific genes. Some examples include ApoE genotyping, which is used to determine patient inclusion/exclusion, and patient stratification in Alzheimer's disease clinical studies. To support patient inclusion/exclusion decision making, we offer turnaround results in 48-72 hours.